Posted elsewhere - The five dropouts in the placeb
Post# of 72440
https://investorshub.advfn.com/boards/read_ms...=136801252
I understand why interim data raised people’s expectations. Come to think of it, bad timing could be the culprit. Here’s what I mean. Let’s assume in the B-OM arm, patient 1 didn’t have severe OM and patient 2 had severe OM. If patient 2 was enrolled before patient 1, patient 2 would be included in the interim analysis and patient 1 would be excluded. Then the interim analysis would look like this.
Incidence rate - 3 out of 9 patients (33.3%)
The top-line data would still be the same.
Incidence rate - 7 out of 19 patients (36.8%)
But it’s a lot closer to the interim %. That’s why interim analysis can be a double-edged sword sometimes. Hope I make sense.